Agile Therapeutics, Inc. Announces Board Appointments
October 06, 2016 at 05:09 pm
Share
On October 5, 2016, the board of directors of Agile Therapeutics, Inc. appointed Al Altomari, the company's President and Chief Executive Officer, as Chairman of the board and Abhijeet Lele as the lead independent director of the board, both effective immediately. In his role as Chairman of the board, Mr. Altomari will lead the board's efforts in overseeing the development and implementation of the company's strategic vision. As Lead Independent Director, Mr. Lele will be responsible for, among other things, leading executive sessions of the board's independent directors and advising the independent board committee chairs in fulfilling their responsibilities to the board. Mr. Altomari and Mr. Lele have been members of the board since February 2004 and May 2010, respectively.
Agile Therapeutics, Inc. is a women's healthcare company, which is engaged in fulfilling the unmet health needs of women. Its product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Its initial product, Twirla, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive. Twirla is based on its proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. Twirla (levonorgestrel and ethinyl estradiol) transdermal system is a once-weekly combined hormonal contraceptive (CHC) patch that contains the active ingredients levonorgestrel (LNG), a type of progestin, and ethinyl estradiol (EE), a type of estrogen. Its potential product pipeline consists of two types of product candidates: a progestin-only (P-only) contraceptive patch and potential Twirla line extensions.